Further, AspenBio Pharma said it promoted Mark Colgin to a new position of chief scientific officer.
“We are very grateful for Rich’s invaluable contribution over the last few years as the company advanced a number of important products to late stage development,” stated Faulkner. “We wish him the very best in his endeavors.”
Greg Pusey, vice chairman of AspenBio, commented: “We continue to achieve important milestones for AspenBio, including the recent addition of board members with significant industry expertise followed by the appointments of highly accomplished members to our executive management team. With today’s addition of Dr. Caspari, Daryl Faulkner has now assembled an executive team which has more than 100 years’ combined industry related experience.”